ArriVent BioPharma (AVBP) Equity Average (2023 - 2026)

ArriVent BioPharma has disclosed Equity Average across 4 years of filings, most recently posting $315.6 million for Q1 2026.

• Equity Average for Q1 2026 came in at $315.6 million, up 37.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $315.6 million (up 37.16% YoY), and the FY2025 annual result was $282.4 million, up 440.75% from the prior year.
• Equity Average came in at $315.6 million for Q1 2026 at ArriVent BioPharma, up from $306.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $315.6 million in Q1 2026 to a low of -$142.9 million in Q4 2023.
• The 4-year median for Equity Average is $248.8 million (2024), against an average of $160.3 million.
• Across the five-year window, Equity Average jumped 385.03% in 2024 and declined 26.36% in 2025, its largest moves.
• ArriVent BioPharma's Equity Average stood at -$142.9 million in 2023, then surged by 287.25% to $267.6 million in 2024, then advanced by 14.4% to $306.1 million in 2025, then grew by 3.1% to $315.6 million in 2026.
• The last three Equity Average figures came in at $315.6 million (Q1 2026), $306.1 million (Q4 2025), and $277.4 million (Q3 2025), per Business Quant data.